Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Investigate the Safety and Efficacy of ABBV-105 and Upadacitinib Given Alone or in Combination in Participants With Moderately to Severely Active Systemic Lupus Erythematosus

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03978520
Recruitment Status : Recruiting
First Posted : June 7, 2019
Last Update Posted : September 6, 2019
Sponsor:
Information provided by (Responsible Party):
AbbVie

Brief Summary:
The main objective of this study is to evaluate the safety and efficacy of ABBV-105, upadacitinib, and ABBV-599 vs placebo for the treatment of signs and symptoms of SLE in participants with moderately to severely active SLE and to define doses for further development.

Condition or disease Intervention/treatment Phase
Systemic Lupus Erythematosus (SLE) Drug: ABBV-105 Drug: Placebo for ABBV-105 Drug: Upadacitinib Drug: Placebo for upadacitinib Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 310 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 2 Study to Investigate the Safety and Efficacy of ABBV-105 and Upadacitinib Given Alone or in Combination (ABBV-599 Combination) in Subjects With Moderately to Severely Active Systemic Lupus Erythematosus
Actual Study Start Date : July 25, 2019
Estimated Primary Completion Date : September 16, 2021
Estimated Study Completion Date : March 18, 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lupus

Arm Intervention/treatment
Experimental: Group 1: Upadacitinib and ABBV-105
Participants will be administered with ABBV-105 dose A and upadacitinib dose A
Drug: ABBV-105
ABBV-105 is administered orally as capsule

Drug: Upadacitinib
Upadacitinib is administered orally as a tablet

Experimental: Group 2: Upadacitinib and ABBV-105
Participants will be administered with ABBV-105 dose A and upadacitinib dose B
Drug: ABBV-105
ABBV-105 is administered orally as capsule

Drug: Upadacitinib
Upadacitinib is administered orally as a tablet

Experimental: Group 3: ABBV-105 and Placebo for Updadacitinib
Participants will be administered with ABBV-105 dose A and placebo for upadacitinib
Drug: ABBV-105
ABBV-105 is administered orally as capsule

Drug: Placebo for upadacitinib
Placebo for upadacitinib is administered orally as a tablet

Experimental: Group 4: Upadacitinib and Placebo for ABBV-105
Participants will be administered with placebo for ABBV-105 and upadacitinib dose A
Drug: Placebo for ABBV-105
Placebo for ABBV-105 is administered orally as capsule

Drug: Upadacitinib
Upadacitinib is administered orally as a tablet

Experimental: Group 5: Placebo for ABBV-105 and Placebo for Upadacitinib
Participants will be administered with placebo for ABBV-105 and placebo for upadacitinib
Drug: Placebo for ABBV-105
Placebo for ABBV-105 is administered orally as capsule

Drug: Placebo for upadacitinib
Placebo for upadacitinib is administered orally as a tablet




Primary Outcome Measures :
  1. SLE Responder Index (SRI)-4 and steroid dose <= 10 mg prednisone equivalent QD [ Time Frame: Week 24 ]
    Composite of SRI-4 and steroid dose <= 10 mg prednisone equivalent QD based on improvement in disease activity without worsening of the overall condition or the development of significant disease activity in new organ systems is evaluated.


Secondary Outcome Measures :
  1. SLE Responder Index (SRI)-4 [ Time Frame: Up to Week 48 ]
    SRI is a composite responder index based on improvement in disease activity without worsening of the overall condition or the development of significant disease activity in new organ systems.

  2. SLE Responder Index (SRI)-5 [ Time Frame: Up to Week 48 ]
    SRI is a composite responder index based on improvement in disease activity without worsening of the overall condition or the development of significant disease activity in new organ systems.

  3. SLE Responder Index (SRI)-6 [ Time Frame: Up to Week 48 ]
    SRI is a composite responder index based on improvement in disease activity without worsening of the overall condition or the development of significant disease activity in new organ systems.

  4. SLE Responder Index (SRI)-7 [ Time Frame: Up to Week 48 ]
    SRI is a composite responder index based on improvement in disease activity without worsening of the overall condition or the development of significant disease activity in new organ systems.

  5. SLE Responder Index (SRI)-8 [ Time Frame: Up to Week 48 ]
    SRI is a composite responder index based on improvement in disease activity without worsening of the overall condition or the development of significant disease activity in new organ systems.

  6. British Isles Lupus Assessment Group (BILAG) Based Combined Lupus Assessment (BICLA) [ Time Frame: Up to Week 48 ]
    BICLA is a composite responder index based on improvement in organ systems without worsening of the overall condition and improvement in disease activity.

  7. Lupus Low Disease Activity State (LLDAS) [ Time Frame: Up to Week 48 ]
    LLDAS is a state of low disease activity based on SLEDAI score, absence of SLE disease activity in major organ systems and new disease activity, Physician's Global Assessment, and concomitant medication usage. SLEDAI is the SLE disease activity index focuses on high-impact disease manifestations across organ systems. Scores range from 0 to 105, with higher scores indicating more severe disease

  8. Change in Systemic Lupus Erythematosus Disease Activity Index (SLEDAI)-2000 (2K) from Baseline [ Time Frame: From Baseline (Week 0) to Week 48 ]
    SLEDAI-2K is global SLE disease activity index that focuses on high-impact disease manifestations across the organ systems.

  9. Change in Steroid Burden from Baseline [ Time Frame: From Baseline (Week 0) to Week 48 ]
    Steroid Burden is measured as milligrams (mg) of prednisolone administered.

  10. Number of flares by Safety of Estrogens in Lupus Erythematosus National Assessment (SELENA) SLEDAI flare index [ Time Frame: Up to Week 48 ]
    SELENA SLEDAI flare index defines SLE flares using the SLEDAI-2K score, disease activity scenarios, treatment changes, and Physician's Global Assessment of Disease Activity.

  11. Time to first flare by SELENA SLEDAI flare index after first study drug administration [ Time Frame: Up to Week 48 ]
    SELENA SLEDAI flare index defines SLE flares using the SLEDAI-2K score, disease activity scenarios, treatment changes, and Physician's Global Assessment of Disease Activity.

  12. Reduction in Number of Tender or Swollen Lupus joints [ Time Frame: Up to Week 48 ]
    Reduction in number of Tender or Swollen Lupus joints of those starting with >= 6 affected joints is assessed by physical examination

  13. Reduction in Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) activity score by 50% [ Time Frame: Up to Week 48 ]
    CLASI is an index used to assess cutaneous manifestations of SLE summarizing the activity of the disease.

  14. Change in British Isles Lupus Assessment Group (BILAG) from Baseline [ Time Frame: From Baseline (Week 0) to Week 48 ]
    BILAG is a global SLE disease activity index designed on the basis of the physician's intention to treat, focusing on changes in disease manifestations.

  15. Change in Physician's Global Assessment from Baseline [ Time Frame: From Baseline (Week 0) to Week 48 ]
    Participant's overall disease activity due to SLE, as compared with all possible patients with SLE is assessed by physician.

  16. Change in Functional Assessment of Chronic Illness Therapy - fatigue (FACIT-F) from Baseline [ Time Frame: From Baseline (Week 0) to Week 48 ]
    FACIT-F is a patient-reported questionnaire developed to assess fatigue. The responses to the items on the FACIT-F questionnaire are each measured on a 4-point Likert scale.

  17. Change in Short Form (SF)-36 from Baseline [ Time Frame: From Baseline (Week 0) to Week 48 ]
    SF-36 is a general Health Related Quality of Life (HRQoL) instrument which comprises 36 total questions targeting participant's functional health and well-being.

  18. Change Lupus Quality of Life (LupusQoL) from Baseline [ Time Frame: From Baseline (Week 0) to Week 48 ]
    The Lupus Quality of Life (LupusQoL) is a disease-specific Health Related Quality of Life (HRQoL) patient reported outcome (PRO) instrument.

  19. Change in Pain Numerical Rating Scale (NRS) from Baseline [ Time Frame: From Baseline (Week 0) to Week 48 ]
    The pain NRS scale is a single item questionnaire in which participants are asked to rate the overall pain level. The pain NRS scores range from 0 to 10, with higher scores indicating a higher level of pain.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Participant has clinical diagnosis of SLE at least 24 weeks prior to screening, meeting at least 4 of the 11 revised Criteria for Classification of SLE according to the 1997 Update of the 1982 American College of Rheumatology (ACR) OR meeting at least 4 of the 2012 SLICC classification criteria, including at least 1 clinical criterion and 1 immunologic criterion.
  • At Screening, must have at least one of the following:

    • antinuclear antibody(ANA)+ (titer >= 1:80)
    • anti-dsDNA+
    • anti-Smith+
  • SLEDAI-2K >= 6 as reported and independently adjudicated (clinical score >= 4, excluding lupus headache and/or organic brain syndrome) at Screening. If 4 points of the required entry points are for arthritis, there must also be a minimum of 3 tender and 3 swollen joints. If participant has rash and PI considers it to be attributable to SLE, participant must consent to skin photograph collection for adjudication.
  • Physician's Global Assessment (PhGA) >= 1 during screening period
  • Background treatment, stable for 30 days, at Baseline with prednisone, antimalarials, azathioprine, mycophenolate, leflunomide cyclosporine, tacrolimus, and/or methotrexate (MTX).

    • The combination of background treatment with antimalarial(s) and/or prednisone (or equivalent) and a single, but not multiple, additional immunosuppressant is permitted.

Exclusion Criteria:

- Participant using intravenous (IV) or intramuscular (IM) corticosteroids greater than or equal to a 40 mg prednisone-equivalent bolus within 30 days of planned randomization.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03978520


Contacts
Layout table for location contacts
Contact: ABBVIE CALL CENTER 847.283.8955 abbvieclinicaltrials@abbvie.com

  Show 135 Study Locations
Sponsors and Collaborators
AbbVie
Investigators
Layout table for investigator information
Study Director: AbbVie Inc. AbbVie

Layout table for additonal information
Responsible Party: AbbVie
ClinicalTrials.gov Identifier: NCT03978520     History of Changes
Other Study ID Numbers: M19-130
2019-000638-20 ( EudraCT Number )
First Posted: June 7, 2019    Key Record Dates
Last Update Posted: September 6, 2019
Last Verified: September 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Clinical Study Report (CSR)
Analytic Code
Time Frame: Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.
Access Criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.
URL: https://www.abbvie.com/our-science/clinical-trials/clinical-trials-data-and-information-sharing/data-and-information-sharing-with-qualified-researchers.html

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by AbbVie:
Systemic Lupus Erythematosus (SLE)
ABBV-105
Upadacitinib
ABBV-599
Additional relevant MeSH terms:
Layout table for MeSH terms
Lupus Erythematosus, Systemic
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases